<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630742</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1076</article-id><article-id pub-id-type="publisher-id">ofx163.1076</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sax</surname><given-names>Paul E</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Dejesus</surname><given-names>Edwin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Crofoot</surname><given-names>Gordon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Ward</surname><given-names>Douglas</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Benson</surname><given-names>Paul</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Lilian</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Kirsten</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Collins</surname><given-names>Sean</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Hal</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Andrew</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Quirk</surname><given-names>Erin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Division of Infectious Diseases, Brigham and Women’s Hospital</institution>, <addr-line>Boston, Massachusetts</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>Orlando Immunology Center</institution>, <addr-line>Orlando, Florida</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>The Crofoot Research Center</institution>, <addr-line>Houston, Texas</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>Dupont Circle Physicians Group</institution>, <addr-line>Washington, DC</addr-line></aff><aff id="AF0005">
<label>5</label>
<institution>Be Well Medical</institution>, <addr-line>Berkley, Michigan</addr-line></aff><aff id="AF0006">
<label>6</label>
<institution>Gilead Sciences</institution>, <addr-line>Foster City, California</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 156. HIV: Antiretroviral Therapy</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S426</fpage><lpage>S427</lpage><permissions><copyright-statement>© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1076.pdf"></self-uri><abstract><title><offsets xml_i="5589" xml_f="5597" txt_i="11" txt_f="19">Abstract</offsets></title><sec id="s1"><title><offsets xml_i="5625" xml_f="5635" txt_i="20" txt_f="30">Background</offsets></title><p><offsets xml_i="5646" xml_f="5911" txt_i="31" txt_f="296">Integrase strand transfer inhibitors (INSTIs) are widely recommended for initial HIV-1 treatment. Bictegravir (BIC, B) is a novel, once-daily INSTI with potent antiviral activity being developed in coformulation with emtricitabine and tenofovir alafenamide (F/TAF).</offsets></p></sec><sec id="s2"><title><offsets xml_i="5941" xml_f="5948" txt_i="298" txt_f="305">Methods</offsets></title><p><offsets xml_i="5959" xml_f="6476" txt_i="306" txt_f="820">In this Phase 2 study, treatment naïve, HIV-infected adults were randomized 2:1 to receive blinded treatment with BIC or dolutegravir (DTG) coadministered with open label F/TAF (200/25 mg). After all participants completed 48 weeks, they were unblinded and switched to a single fixed-dose combination tablet of B/F/TAF 50/200/25 mg. The proportion of participants with HIV-1 RNA &lt;50 copies/mL (c/mL) was assessed at Week (W) 24 and W48 of the blinded phase and 12 weeks after switching to open label B/F/TAF (W72).</offsets></p></sec><sec id="s3"><title><offsets xml_i="6506" xml_f="6513" txt_i="822" txt_f="829">Results</offsets></title><p><offsets xml_i="6524" xml_f="6718" txt_i="830" txt_f="1024">Of 98 participants enrolled in the blinded treatment phase, 65 were randomized to BIC+F/TAF and 33 to DTG+F/TAF. Most were male, had asymptomatic HIV infection, with median HIV-1 RNA 4.4–4.5 log</offsets><sub><offsets xml_i="6723" xml_f="6725" txt_i="1024" txt_f="1026">10</offsets></sub><offsets xml_i="6731" xml_f="7106" txt_i="1026" txt_f="1395"> c/mL. The proportion of subjects with HIV-1 RNA &lt;50 c/mL at W24 was 97% for the BIC arm and 94% for the DTG arm, and at W48 was 97% and 91%, respectively (Table). All 92 participants who completed the blinded phase were switched to B/F/TAF at W60. At W72 or 12 weeks after switching to open-label B/F/TAF, 99% (91/92) maintained HIV-1 RNA &lt;50 c/mL (98% prior BIC arm [</offsets><italic><offsets xml_i="7114" xml_f="7117" txt_i="1395" txt_f="1398">N =</offsets></italic><offsets xml_i="7126" xml_f="7152" txt_i="1398" txt_f="1424"> 62]; 100% prior DTG arm [</offsets><italic><offsets xml_i="7160" xml_f="7163" txt_i="1424" txt_f="1427">N =</offsets></italic><offsets xml_i="7172" xml_f="7546" txt_i="1427" txt_f="1801"> 30]) and one individual withdrew prior to the analysis. No viral resistance was detected in participants treated with BIC. No participants discontinued open label B/F/TAF due to an adverse event, there were no treatment-related serious adverse events and no deaths. One individual on BIC previously discontinued due to an adverse event of urticaria following the W24 visit.</offsets></p></sec><sec id="s4"><title><offsets xml_i="7576" xml_f="7586" txt_i="1803" txt_f="1813">Conclusion</offsets></title><p><offsets xml_i="7597" xml_f="8083" txt_i="1814" txt_f="2300">All participants switched from DTG+F/TAF to open-label B/F/TAF maintained virologic suppression, with none discontinuing due to adverse events. During 72 weeks of follow-up, no treatment-emergent resistance to any components was detected in participants taking B/F/TAF. B/F/TAF demonstrated durable virologic suppression in naïve patients through W72 and was safe and effective after switching from DTG + F/TAF, further study in treatment naïve and experienced populations is warranted.</offsets></p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0466"></graphic></fig></sec><sec id="s5"><title><offsets xml_i="8243" xml_f="8254" txt_i="2302" txt_f="2313">Disclosures</offsets></title><p><offsets xml_i="8265" xml_f="8266" txt_i="2314" txt_f="2315">
</offsets><bold><offsets xml_i="8272" xml_f="8281" txt_i="2315" txt_f="2324">P. E. Sax</offsets></bold><offsets xml_i="8288" xml_f="8679" txt_i="2324" txt_f="2715">, Gilead: Consultant and Investigator, Consulting fee, Research grant and Research support; BMS: Consultant and Investigator, Consulting fee, Research grant and Research support; GlaxoSmithKline/ViiV: Consultant and Investigator, Consulting fee, Research grant and Research support; AbbVie: Consultant, Consulting fee; Janssen: Consultant, Consulting fee; Merck: Consultant, Consulting fee; </offsets><bold><offsets xml_i="8685" xml_f="8695" txt_i="2715" txt_f="2725">E. Dejesus</offsets></bold><offsets xml_i="8702" xml_f="8902" txt_i="2725" txt_f="2925">, Gilead Sciences: Consultant, Investigator and Speaker’s Bureau, Consulting fee and Speaker honorarium; Janssen: Consultant, Investigator and Speaker’s Bureau, Consulting fee and Speaker honorarium; </offsets><bold><offsets xml_i="8908" xml_f="8918" txt_i="2925" txt_f="2935">G. Crofoot</offsets></bold><offsets xml_i="8925" xml_f="9113" txt_i="2935" txt_f="3123">, Gilead: Investigator and Scientific Advisor, Advisory honorarium and Research grant; ViiV: Investigator and Scientific Advisor, Advisory honorarium, Research grant and Research support; </offsets><bold><offsets xml_i="9119" xml_f="9126" txt_i="3123" txt_f="3130">D. Ward</offsets></bold><offsets xml_i="9133" xml_f="9175" txt_i="3130" txt_f="3172">, Gilead: Investigator, Research support; </offsets><bold><offsets xml_i="9181" xml_f="9190" txt_i="3172" txt_f="3181">P. Benson</offsets></bold><offsets xml_i="9197" xml_f="9354" txt_i="3181" txt_f="3338">, Gilead Sciences: Investigator, Shareholder and Speaker’s Bureau, Research support and Speaker honorarium; ViiV Healthcare: Investigator, Research support; </offsets><bold><offsets xml_i="9360" xml_f="9366" txt_i="3338" txt_f="3344">L. Wei</offsets></bold><offsets xml_i="9373" xml_f="9417" txt_i="3344" txt_f="3388">, Gilead: Employee and Shareholder, Salary; </offsets><bold><offsets xml_i="9423" xml_f="9431" txt_i="3388" txt_f="3396">K. White</offsets></bold><offsets xml_i="9438" xml_f="9497" txt_i="3396" txt_f="3455">, Gilead Sciences, Inc.: Employee and Shareholder, Salary; </offsets><bold><offsets xml_i="9503" xml_f="9513" txt_i="3455" txt_f="3465">S. Collins</offsets></bold><offsets xml_i="9520" xml_f="9564" txt_i="3465" txt_f="3509">, Gilead: Employee and Shareholder, Salary; </offsets><bold><offsets xml_i="9570" xml_f="9579" txt_i="3509" txt_f="3518">H. Martin</offsets></bold><offsets xml_i="9586" xml_f="9623" txt_i="3518" txt_f="3555">, Gilead Sciences: Employee, Salary; </offsets><bold><offsets xml_i="9629" xml_f="9637" txt_i="3555" txt_f="3563">A. Cheng</offsets></bold><offsets xml_i="9644" xml_f="9688" txt_i="3563" txt_f="3607">, Gilead: Employee and Shareholder, Salary; </offsets><bold><offsets xml_i="9694" xml_f="9702" txt_i="3607" txt_f="3615">E. Quirk</offsets></bold><offsets xml_i="9709" xml_f="9751" txt_i="3615" txt_f="3657">, Gilead: Employee and Shareholder, Salary</offsets></p></sec></abstract><counts><page-count count="2"></page-count></counts></article-meta></front></article>